SIMCERE PHARMACEUTICAL GROUP, ADS
SCR
SCR was delisted on the 23rd of December, 2013.
12 hedge funds and large institutions have $3.23M invested in SIMCERE PHARMACEUTICAL GROUP, ADS in 2013 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 13 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
40% less funds holding
Funds holding: 20 → 12 (-8)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
71% less call options, than puts
Call options by funds: $45K | Put options by funds: $155K
84% less capital invested
Capital invested by funds: $20.1M → $3.23M (-$16.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
+$1.28M |
| 2 |
LOM
Loeb Offshore Management
New York
|
+$480K |
| 3 |
Barclays
London,
United Kingdom
|
+$41.6K |
| 4 |
Morgan Stanley
New York
|
+$10.9K |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$9.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.67M |
| 2 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$4.07M |
| 3 |
SGA
Siguler Guff Advisers
New York
|
-$3.24M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$2.58M |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$959K |
SCR Hedge Fund Activity: Q4 2013 in Review
12 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in SIMCERE PHARMACEUTICAL GROUP, ADS (SCR) for Q4 2013, worth a combined $3.23M — down 84% from $20.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SCR and 5 opened new positions — a net loss of 8 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was SG Americas Securities, opening a new position worth an estimated $1.28M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $5.67M sold.
- 12 institutional investors held SIMCERE PHARMACEUTICAL GROUP, ADS (SCR) as of Q4 2013, down from 20 in Q3 2013.
- Funds reported $3.23M of SIMCERE PHARMACEUTICAL GROUP, ADS stock for Q4 2013, down 84% quarter-over-quarter.
- 5 funds opened new SIMCERE PHARMACEUTICAL GROUP, ADS positions in Q4 2013 and 13 closed out, a net change of -8 holders.
- The largest SIMCERE PHARMACEUTICAL GROUP, ADS buyer in Q4 2013 was SG Americas Securities, an estimated $1.28M added.
- The largest SIMCERE PHARMACEUTICAL GROUP, ADS seller in Q4 2013 was T. Rowe Price Associates, an estimated $5.67M sold.
Based on aggregated 13F filings for Q4 2013.